文献速递妇科生殖医学

分子分型指导年轻子宫内膜癌患者保留生育功能管理的潜力

Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2024-02-24

综述探讨ProMisE分子分型(错配修复缺陷、POLE外切酶域突变、p53表达)在年轻子宫内膜癌患者保留生育功能治疗中的应用潜力。现有证据有限且质量低,但提示错配修复缺陷肿瘤虽经孕激素治疗仍可能复发,POLE突变肿瘤预后良好但仅宫腔镜切除的安全性需进一步研究,p53异常肿瘤预后不良使其保留生育功能的适宜性存疑。

要点

  • 错配修复缺陷肿瘤经孕激素治疗后可能复发,提示需替代治疗,靶向治疗尚待探索。
  • POLE突变肿瘤预后良好,但仅行宫腔镜切除的安全性需进一步研究。
  • p53异常肿瘤预后不良,其保留生育功能治疗的适宜性存疑。

核心结论

  • 现有证据有限且质量低,但为基于分子亚型管理保留生育功能方法提供了见解和未来研究方向。

研究设计与样本

  • 综述总结了现有文献,为未来基于分子分型的子宫内膜癌风险评估研究建立框架。

主要发现

  • 错配修复缺陷肿瘤经孕激素治疗后可能复发,强调需要替代治疗,靶向治疗是新领域尚待探索。
  • POLE突变肿瘤预后良好,但仅宫腔镜切除的安全性需进一步研究。
  • p53异常肿瘤预后不良,对其保留生育功能治疗的适宜性提出疑问。
  • 无特定分子谱(或p53野生型)肿瘤预后相对良好,但具有异质性,需要更精确的生物标志物来有效指导预后较差者的治疗。

临床怎么用

  • 作者认为,解决这些研究空白将促成更精确的指南,以确保保留生育功能治疗的最佳选择。

局限性

  • 现有证据有限且质量低。
  • POLE突变肿瘤仅宫腔镜切除的安全性需进一步研究。
  • 靶向治疗作为错配修复缺陷肿瘤的新领域仍待探索。
  • 无特定分子谱肿瘤具有异质性,需要更精确的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The traditional histological classification system for endometrial carcinoma falls short in addressing the disease's molecular heterogeneity, prompting the need for alternative stratification methods. Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has emerged as a clinically efficient tool to categorize endometrial cancers according to mismatch repair deficiency, POLE exonuclease domain mutations, and p53 expression. However, the application of this classification to fertility-sparing treatments remains unexplored, and current guidelines lack specificity in how it should be used. In this review, we summarize the available literature and establish the framework for future investigations focused on molecular profiling-based risk assessment of endometrial cancer, with the goal of utilizing precision medicine to optimally counsel patients seeking fertility-sparing treatment. While the available evidence is limited and of low quality, it does provide insights and frames future perspectives for managing fertility-sparing approaches on the basis of molecular subtypes. Evidence suggests that mismatch repair-deficient tumors are likely to recur despite progestin therapy, emphasizing the need for alternative treatments, with targeted therapies being a new landscape that still needs to be explored. Tumors with POLE mutations exhibit a favorable prognosis, but the safety of hysteroscopic resection alone requires further investigation. p53 abnormal tumors have an unfavorable prognosis, raising questions about their suitability for fertility-sparing treatment. Lastly, the no specific molecular profile (or p53 wild-type) tumors, while having a relatively good prognosis, are heterogeneous and require more precise biomarkers to effectively guide therapy for those with poorer prognoses. Addressing these research gaps will lead to more precise guidelines to ensure optimal selection for fertility-sparing treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Agusti N, Kanbergs A, Nitecki R, et al. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer. Gynecol Oncol. 2024. PMID: 38402734. doi:10.1016/j.ygyno.2024.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。